Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No ambivalence

Executive Summary

Sanofi's recovery of exclusive rights to the hypnotic Ambien in April 2002 will not "affect in any way their commitment to Plavix or to the upside opportunity with this product," Lane declares. "We...are both very, very, very, very committed to making this one of the most successful brands in the history of the industry"

You may also be interested in...



Sanofi Plavix Superiority Claims Over Aspirin Draw Second FDA Letter

FDA's ad division has issued a second letter to Sanofi-Synthelabo citing the company for making superiority claims for its antiplatelet drug Plavix versus aspirin.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel